Nebulized Corticosteroids in the Treatment of COPD Exacerbations: Systematic Review, Meta-Analysis, and Clinical Perspective

References

1. 1.↵
   goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd. Accessed May 15, 2017.
2. 2.↵
   1. Davies L,
   2. Angus RM,
   3. Calverley PM

   . Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354(9177):456–460.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Niewoehner DE,
   2. Erbland ML,
   3. Deupree RH,
   4. Collins D,
   5. Gross NJ,
   6. Light RW,
   7. et al

   . Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340(25):1941–1947.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Divo M,
   2. Cote C,
   3. de Torres JP,
   4. Casanova C,
   5. Marin JM,
   6. Pinto-Plata V,
   7. et al

   ; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186(2):155–161.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Leuppi JD,
   2. Schuetz P,
   3. Bingisser R,
   4. Bodmer M,
   5. Briel M,
   6. Drescher T,
   7. et al

   . Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013;309(21):2223–2231.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Schuetz P,
   2. Leuppi JD,
   3. Bingisser R,
   4. Bodmer M,
   5. Briel M,
   6. Drescher T,
   7. et al

   . Prospective analysis of adrenal function in patients with acute exacerbations of COPD: the reduction in the use of corticosteroids in exacerbated COPD (REDUCE) trial. Eur J Endocrinol 2015;173(1):19–27.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Barnes PJ

   . Inhaled corticosteroids. Pharmaceuticals 2010;3(3):514–540.

   OpenUrlCrossRef
8. 8.↵
   1. Horvath G,
   2. Wanner A

   . Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J 2006;27(1):172–187.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Barnes PJ

   . Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016;138(1):16–27.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Papi A,
    2. Bellettato CM,
    3. Braccioni F,
    4. Romagnoli M,
    5. Casolari P,
    6. Caramori G,
    7. et al

    . Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173(10):1114–1121.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Hurst JR,
    2. Perera WR,
    3. Wilkinson TM,
    4. Donaldson GC,
    5. Wedzicha JA

    . Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173(1):71–78.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Jen R,
    2. Rennard SI,
    3. Sin DD

    . Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2012;7:587–595.

    OpenUrlPubMed
13. 13.↵
    1. Man SF,
    2. Xuekui Zhang,
    3. Vessey R,
    4. Walker T,
    5. Lee K,
    6. Park D,
    7. Sin DD

    . The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study. Ther Adv Respir Dis 2009;3(2):73–80.

    OpenUrlCrossRefPubMed
14. 14.
    1. Makarova EV,
    2. Varvarina GN,
    3. Menkov NV,
    4. Czapaeva MY,
    5. Lazareva ES,
    6. Kazatskaya ZA,
    7. et al

    . [Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: efficacy, safety, and effects on the serum levels of soluble differentiation molecules.] Ter Arkh 2016;88(3):24–31.

    OpenUrl
15. 15.↵
    1. Sun X,
    2. He Z,
    3. Zhang J,
    4. Deng J,
    5. Bai J,
    6. Li M,
    7. Zhong X

    . Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. Pulm Pharmacol Ther 2015;31:111–116.

    OpenUrl
16. 16.↵
    1. Booth H,
    2. Bish R,
    3. Walters J,
    4. Whitehead F,
    5. Walters EH

    . Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996;51(11):1100–1104.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Valthenen AS,
    2. Knox AJ,
    3. Wisniewski A,
    4. Tattersfield AE

    . Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991;143(6):1317–1321.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Usmani OS,
    2. Ito K,
    3. Maneechotesuwan K,
    4. Ito M,
    5. Johnson M,
    6. Barnes PJ,
    7. Adcock I

    . Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005;172(6):704–712.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Mendes ES,
    2. Rebolledo P,
    3. Campos M,
    4. Wanner A

    . Immediate antiinflammatory effects of inhaled budesonide in patients with asthma. Ann Am Thorac Soc 2014;11(5):706–711.

    OpenUrl
20. 20.↵
    1. Mak JC,
    2. Nishikawa M,
    3. Barnes PJ

    . Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Amer J Physiol 1995;268(1):L41–L46.

    OpenUrl
21. 21.↵
    1. Gibson PG,
    2. Saltos N,
    3. Fakes K

    . Acute anti-inflammatory effects of inhaled budesonide in asthma. Am J Respir Crit Care Med 2001;163(1):32–36.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Ellul-Micallef R,
    2. Johansson SA

    . Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide. Br J Clin Pharmacol 1983;15(4):419–422.

    OpenUrlPubMedWeb of Science
23. 23.↵
    1. Cazzola M,
    2. Santus P,
    3. Di Marco F,
    4. Carlucci P,
    5. Mondoni M,
    6. Materra MG,
    7. Centanni S

    . Onset of action of formoterol/budesonide in singe inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 2004;17(3):121–125.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.
    1. Daley-Yates PT

    . Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol 2015;80(3):372–380.

    OpenUrl
25. 25.
    1. Kharitonov SA,
    2. Donnelly LE,
    3. Montuschi P,
    4. Corradi M,
    5. Collins JV,
    6. Barnes PJ

    . Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 2002;57(10):889–896.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Maltais F,
    2. Ostinelli J,
    3. Bourbeau J,
    4. Tonnel AB,
    5. Jacquemet N,
    6. Haddon J,
    7. et al

    . Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002;165(5):698–703.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Mirici A,
    2. Meral M,
    3. Akqun M

    . Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2003;23(1):55–62.

    OpenUrl
28. 28.↵
    1. Han W,
    2. Zhao X

    . Nebulized budesonide in the treatment of acute exacerbations of chronic obstructive pulmonary disease. J Clin Med Pract 2004;8(12):6–8.

    OpenUrl
29. 29.↵
    1. Guozhong C,
    2. Hui W,
    3. Qi Z,
    4. Fuliang W

    . The effect of inhaled budesonide in persons with acute excerbations of chronic obstructive pulmonary disease. Chin General Pract 2005;8:1667–1668.

    OpenUrl
30. 30.↵
    1. Gunen H,
    2. Hacievliyagil SS,
    3. Yetkin O,
    4. Gulbas G

    . The role of nebulised budesonide in the treatment of acute exacerbations of COPD. Eur Respir J 2007;29(4):660–667.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Nemagouda S

    . Clinical efficacy of nebulized budesonide in acute exacerbation of COPD. J Evol Med Dental Sci 2014;3(15):4121–4131.

    OpenUrl
32. 32.↵
    1. Yilmazel Ucar E,
    2. Araz O,
    3. Meral M,
    4. Sonkaya E,
    5. Saglam L,
    6. Kaynar H,
    7. et al

    . Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations. a randomized control trial. Med Sci Monit 2014;20:513–520.

    OpenUrl
33. 33.↵
    1. Ding Z,
    2. Li X,
    3. Lu Y,
    4. Rong G,
    5. Yang R,
    6. Zhang R,
    7. et al

    . A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2016;121:39–47.

    OpenUrl
34. 34.
    1. Higgins JP,
    2. Green S

    , editors Special topics in statistics. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated Mar 2011]. The Cochrane Collaboration, 2011. http://handbook.cochrane.org. Accessed May 2, 2017.
35. 35.↵
    1. Beeh KM,
    2. Beier J,
    3. Donohue JF

    . Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res 2012;13:52.

    OpenUrlPubMed
36. 36.↵
    1. Higgins JP,
    2. Green S

    1. Sterne J,
    2. Egger M,
    3. Moher D

    . Addressing reporting biases. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated Mar 2011] The Cochrane Collaboration, 2011. http://handbook.cochrane.org. Accessed February 1, 2018.
37. 37.↵
    1. Morice AH,
    2. Morris D,
    3. Lawson-Matthew P

    . A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther 1996;60(6):675–678.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Zhai Y,
    2. Zhang H,
    3. Sun T,
    4. Ye M,
    5. Liu H,
    6. Zheng R

    . Comparative efficacies of inhaled corticosteroids and systemic corticosteroids in treatment of chronic obstructive pulmonary disease exacerbations: a systematic review and meta-analysis. J Aerosol Med Pulm Drug Deliv 2017;30(5):289–298.

    OpenUrl
39. 39.↵
    1. Pleasants R,
    2. Herrick H,
    3. Liao W,
    4. Ohar J

    . Use of a US population-based survey to describe the relationship of COPD and co-morbidities [abstract]. Eur Respir J 2011;38(Suppl 55):1025.

    OpenUrl
40. 40.↵
    1. Magnussen H,
    2. Disse B,
    3. Rodriguez-Roisin R,
    4. Kirsten A,
    5. Watz H,
    6. Tetzlaff K,
    7. et al

    : WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371(14):1285–1294.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    1. Alangari AA

    . Corticosteroids in the treatment of acute asthma. Ann Thorac Med 2014;9(4):187–192.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Greene MA,
    2. Gordon A,
    3. Boltax AJ

    . Clinical and cardiodynamic effects of adrenocortical steroids in congestive heart failure. Circulation 1960;21:661–671.

    OpenUrlAbstract/FREE Full Text
43. 43.↵
    Pulmicort Respules [package insert]. Wilmington, DE: Astra Zeneca Pharmaceuticals LP; 2009.
44. 44.↵
    Budesonide inhalation suspension [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2016.
45. 45.↵
    1. Scarfone RJ,
    2. Loiselle JM,
    3. Wiley JF II.,
    4. Decker JM,
    5. Henretig FM,
    6. Joffe MD

    . Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Ann Emerg Med 1995;26(4):480–486.

    OpenUrlCrossRefPubMedWeb of Science
46. 46.↵
    1. McKenzie JE,
    2. Cruz-Rivera M

    . Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004;38(6):967–972.

    OpenUrlCrossRefPubMed
47. 47.↵
    1. Devadason SG,
    2. Everard ML,
    3. Linto JM,
    4. Le Souëf PN

    . Comparison of drug delivery from conventional versus “Venturi” nebulizers. Eur Respir J 1997;10(11):2479–2483.

    OpenUrlAbstract
48. 48.
    1. Barry PW,
    2. O'Callaghan C

    . An in vitro analysis of the output of budesonide from different nebulizers. J Allergy Clin Immunol 1999;104(6):1168–1173.

    OpenUrlCrossRefPubMedWeb of Science